Next-generation sequencing, should I use anti-HER2 therapy for HER2 -amplified tumors off-label? Illustrating an extrapolation framework.

MLA

Cho, Doah, et al. “Next-Generation Sequencing, Should I Use Anti-HER2 Therapy for HER2 -Amplified Tumors off-Label? Illustrating an Extrapolation Framework.” Therapeutic Advances in Medical Oncology, July 2022, pp. 1–11. EBSCOhost, https://doi.org/10.1177/17588359221112822.

APA

Cho, D., Lord, S. J., Simes, J., Cooper, W., Friedlander, M., Bae, S., & Lee, C. K. (2022). Next-generation sequencing, should I use anti-HER2 therapy for HER2 -amplified tumors off-label? Illustrating an extrapolation framework. Therapeutic Advances in Medical Oncology, 1–11. https://doi.org/10.1177/17588359221112822

Chicago

Cho, Doah, Sarah J. Lord, John Simes, Wendy Cooper, Michael Friedlander, Susie Bae, and Chee Khoon Lee. 2022. “Next-Generation Sequencing, Should I Use Anti-HER2 Therapy for HER2 -Amplified Tumors off-Label? Illustrating an Extrapolation Framework.” Therapeutic Advances in Medical Oncology, July, 1–11. doi:10.1177/17588359221112822.